Nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb) and 2 cycles of platinum-based (platinum-doublet) chemotherapy has a marketing authorisation for 'the first-line treatment of metastatic non-small-cell lung cancer in adults whose tumours have no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation'.
The dosage schedule is available in the summary of product characteristics.
The list price of nivolumab is £2,633 per 240 mg per 24‑ml vial (excluding VAT; BNF online, accessed May 2021). The list price of ipilimumab is £15,000 per 200 mg per 40‑ml vial (excluding VAT; BNF online, accessed May 2021). The company has commercial arrangements for nivolumab and ipilimumab. These make nivolumab and ipilimumab available to the NHS with discounts, which would have applied to this indication if the technology had been recommended. The size of the discounts is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discounts.